lestaurtinib has been researched along with Thyroid Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrett, JW; Boutros, PC; Datti, A; Fung, K; Lacefield, JC; Leong, HS; Lowerison, M; MacNeil, D; Mymryk, JS; Nichols, AC; Pinto, N; Prokopec, SD; Ruicci, KM; Searle, K; Vizeacoumar, F; Yoo, J | 1 |
| Ball, DW; Denmeade, SR; Dionne, C; Jones-Bolin, S; Nelkin, BD; Park, JI; Rosen, M; Ruggeri, B; Strock, CJ | 1 |
2 other study(ies) available for lestaurtinib and Thyroid Neoplasms
| Article | Year |
|---|---|
Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbazoles; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Dose-Response Relationship, Drug; Furans; Humans; Janus Kinase 2; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2018 |
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Topics: Animals; Carbazoles; Carcinoma, Medullary; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Furans; Growth Inhibitors; Humans; Indoles; Male; Mice; Mice, Nude; Multiple Endocrine Neoplasia Type 2b; Mutation; Oncogene Proteins; Phosphorylation; Prodrugs; Proto-Oncogene Proteins c-ret; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |